Диссертация (1140202), страница 17
Текст из файла (страница 17)
Guillevin L, Pagnoux C, Teixeira L. Microscopic polyangiitis. In: Ball G,Bridges Jr S, editors. Vasculitis. Oxford: Oxford University Press; 2008.p. 355–64.78. Ueda S, Matsumoto M, Ahn T, Adachi S, Oku K, Takagi M, et al.Microscopic polyangiitis complicated with massive intestinal bleeding. JGastroenterol 2001;36:264–70.79. ZhangW, Zhou G, Shi Q, Zhang X, Zeng XF, Zhang FC. Clinical analysisof nervous system involvement in ANCA-associated system vasculitides.Clin Exp Rheumatol 2009; 27:S65–9.11080.
Hattori N, Mori K, Misu K, Koike H, Ichimura M, Sobue G. Mortalityand morbidity in peripheral neuropathy associated Churg–Strausssyndrome and microscopic polyangiitis. J Rheumatol 2002;29:1408–14.81. Furukawa Y, Matsumoto Y, Yamada M. Hypertrophic pachymeningitis asan initial and cardinal manifestation of microscopic polyangiitis.Neurology 2004;63:1722–4.82. Ku BD, Shin HY. Multiple bilateral non-hemorrhagic cerebral infarctionsassociated with microscopic polyangiitis. Clin Neurol Neurosurg2009;111:904–6.83.
Adu D, Howie AJ, Scott DG, Bacon PA, McGonigle RJ, Micheal J.Polyarteritis and the kidney. Q J Med Mar 1987;62:221–37.84. Serra A, Cameron J, Turner D, Hartley B, Ogg C, Neild G, et al.Vasculitis affecting the kidney: presentation, histopathology and longterm outcome. QJM 1984;53: 181–207.85. Veldman J. Immune-mediated sensorineural hearing loss. Auris NasusLarynx 1998;25:309–17.86. Liu LJ, Chen M, Yu F, Zhao MH, Wang HY: Evaluation of a newalgorithm in classification of systemic vasculitis. Rheumatology (Oxford)2008, 47:708–712 Kallenberg CG.
The diagnosis and classification ofmicroscopic polyangiitis. J Autoimmun 2014;48-49:90–3.87. J. Yoo, H.J. Kim, S.S. Ahn, S.M. Jung, J.J. Song, Y.-B. Park, S.-W. LeeThe utility of the ACR/EULAR 2017 provisional classification criteria forgranulomatosis with polyangiitis in Korean patients with antineutrophilcytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol 2018; 36(Suppl. 111): S85-S87.88.
M. Hilhorst, B. Wilde, P. van Breda Vriesman, P. van Paassen, J. W.Cohen Tervaert, and for the Limburg Renal Registry, “Estimating renalsurvival using the ANCA-associated GN classification,” Journal of theAmerican Society of Nephrology, vol. 24, no. 9, pp. 1371–1375, 2013.11189. A. Tanna, L. Guarino, F. W.
K. Tam et al., “Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluationof the international histological classification and other prognosticfactors,” Nephrology Dialysis Transplantation, vol. 30, no. 7, pp. 1185–1192, 2015.90. A. E. Berden, F. Ferrario, E. C. Hagen et al., “Histopathologicclassification of ANCA-associated glomerulonephritis,” Journal of theAmerican Society of Nephrology, vol. 21, no. 10, pp. 1628–1636, 2010.91.
I. M. Bajema, E. C. Hagen, B. E. Hansen et al., “The renal histopathologyin systemic vasculitis: an international survey study of inter- and intraobserver agreement,” Nephrology Dialysis Transplantation, vol. 11, no.10, pp. 1989–1995, 1996.92. Chang DY, Wu LH, Liu G, Chen M, Kallenberg CG, Zhao MH.
Re-evaluation of the histopathologic classification of ANCA-associatedglomerulonephritis: a study of 121 patients in a single center. NephrolDial Transplant. 2012;27(6):2343-9. doi: 10.1093/ndt/gfr64393. Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol1997;8:306–22.94. van der Woude, F. J. et al. Autoantibodies against neutrophils andmonocytes: tool for diagnosis and marker of disease activity in Wegener’sgranulomatosis. Lancet 1, 425–429 (1985)95. Cohen Tervaert, J.
et al. Wegener’s Granulomatosis and anticytoplasmicantibodies: the Groningen experience. APMIS 97 (Suppl. 6), 36 (1989).96. Goldschmeding, R.et al. Wegener’s granulomatosis autoantibodiesidentify a novel diisopropylfluorophosphate-binding protein in thelysosomes of normal human neutrophils. J. Clin. Invest. 84, 1577–1587(1989).11297. Niles, J. L., McCluskey, R. T., Ahmad, M.
F., Arnaout, M. A. Wegener’sgranulomatosis autoantigen is a novel neutrophil serine proteinase. Blood74, 1888–1893 (1989).98. Jenne, D. E., Tschopp, J., Ludemann, J., Utecht, B. & Gross, W. L.Wegener’s autoantigen decoded. Nature 346, 520 (1990)99. Csernok, E., Moosig, F. Current and emerging techniques for ANCAdetection in vasculitis. Nat. Rev.Rheumatol.
10, 494–501 (2014).100.Cohen Tervaert, J. W., Damoiseaux, J. Antineutrophil cytoplasmicautoantibodies: how are they detected andwhat is their use for diagnosis,classification and follow-up? Clin. Rev. Allergy Immunol. 43, 211–219(2012)101.Cohen Tervaert, J. W., Damoiseaux, J. Fifty years of antineutrophilcytoplasmic antibodies (ANCA) testing: do we need to revise theinternational consensus statement on testing and reporting on ANCA.APMIS Suppl.
117 (Suppl. 127), 55–59 (2009).102.Rasmussen, N., Wiik, A., Jayne, D. R. A historical essay ondetection of anti-neutrophil cytoplasmic antibodies. Nephrol. Dial.Transplant. 30 (Suppl. 1), i8–i13 (2015).103.Hagen, E. C. et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis.EC/BCR project for ANCA assay standardization. Kidney Int. 53, 743–753 (1998).104.Savige, J.
et al. International consensus statement on testing andreporting of antineutrophil cytoplasmic antibodies (ANCA). Am. J. Clin.Pathol. 111, 507–513 (1999).105.Bossuyt X., Cohen Tervaert J.-W., Arimura Y., Blockmans D,Flores-Suárez L. F., Guillevin L., Hellmich B., Jayne D., Jennette J.C.,Kallenberg C., Moiseev S., Novikov P., Radice A., Savige J., Sinico R.A.,Specks U., van Paassen P, Zhao M., Rasmussen N., Damoiseaux J.
and113Csernok E. Revised 2017 international consensus on testing of ANCAs ingranulomatosiswithpolyangiitisandmicroscopicpolyangiitis.Rheumatology. 2017.106.Jayne D. Challenges in the management of the microscopicpolyangiitis: Past,present and future. Curr Opin Rheumatol. 2008;20:3–9.107.Ravindran V, Watts RA. Pulmonary haemorrhage in ANCAassociated vasculitis. Rheumatology. 2010;49:1410–2.108.Jennette JC, Thomas DB, Falk RJ.Microscopic polyangiitis(microscopic polyarteritis). Semin Diagn Pathol 2001;18:3–13.109.Thickett DR, Richter AG, Nathani N, et al. Pulmonarymanifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positivevasculitis. Rheumatology.
2006;45:261–8.110.Rolla G, Heffler E, Guida G, et al. Exhaled NO in diffuse alveolarhaemorrhage. Thorax. 2005;60:614–5.111.Iftikhar IH, Alghothani L, Sardi A, et al. Transbronchial lungcryobiopsy and video-assisted lung thorachoscopic lung biopsy in thediagnosis of diffuse parenchymal disease: e meta-analysis of diagnostictestaccuracy.AnnAmThoracSoc.2017;doi:10.1513/AnnalsATS.201701-086SR. This metaanalysis secures the safety oftransbronchial lung biopsies versus video-assisted thoracoscopic tissueobtainment, with similar diagnostic accuracy in diffuse lung diseases.112.Ussavarungsi K, Kern R, Anja C, et al.
Transbronchial cryobiopsyin diffuse parenchymal lung disease: retrospective analysis of 74 cases.Chest. 2017;151:400–8. An article describing a recent technique to obtainadequate samples in diffuse lung parenchymal disease from differentetiologies.113.Lally L, Spiera F. Pulmonary vasculitis. Rheum Dis Clin NAm.2015;41:315–31.114114.Filleul, O., Madhoun, P., & Vanhaeverbeek, M. (2014). ANCA-negative associated vasculitis initially presenting with pulmonaryembolism.ActaClinicaBelgica,69(5),382–385.doi:10.1179/2295333714y.0000000041115.Said G, Lacroix C.
Primary and secondary vasculitic neuropathy. JNeurol 2005; 252:633–641.116.Falk R. J., Moore D. T., Hogan S. L., Jennette J. C. A renal biopsyin essential for the management of ANCA-positive patients withglomerulonephritis // Sarcoidosis Vasc Diffuse Lung Dis. ‒ 1996. ‒ T. 13,№ 3. ‒ C. 230-1.117.Luqmani R.A.
et al. Birmingham Vasculitis Activity Score (BVAS)// QJM. 1994. Vol. 87. № 11. Р. 671-8.118.Suppiah R. et al. A cross-sectional study of the BirminghamVasculitis Activity Score version 3 in systemic vasculitis // Rheumatology(Oxford). 2011. Vol.50. № 5. Р. 899-905119.Yoo J., Jung S.M., Song J.J., Park Y-B., Lee S.-W. Birminghamvasculitis activity and chest manifestation at diagnosis can predicthospitalisedinfectioninANCA-associatedvasculitis.ClinicalRheumatology. 2018.
https://doi.org/10.1007/s10067-018-4067-5120.Bai Y.-H., Li Z., Chang D.-Y., Chen M., Kallenberg G.M. andZhao M.-H. The BVAS is an independent predictor of cardiovascularevents and cardiovascular disease-related mortality in patients withANCA-associated vasculitis. Cardiovascular events in AAV.
Seminars inArthritisandRheumatism.http://dx.doi.org/10.1016/j.semarthrit.2017.07.004121.Exley A.R. et al. Development and initial validation of the VDI //Arthritis Rheum. 1997. Vol. 40. Р. 371–80.122.Bhamra K., Luqmani R. Damage assessment in ANCA-associatedvasculitis //Curr Rheumatol Rep. 2012. Vol. 14. № 6.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
